Dr J�rg T�ubel, will be presenting again at the DIA 3rd Cardiac Safety Workshop in Japan, taking place in Tokyo from 28-29 May 2012.The 3rd Cardiac Safety Workshop in Japan will explore topics surrounding the future of the TQT study, including the emerging intensive QT studies, the use of positive controls for assay sensitivity, the risks involved in TQT studies, as well as other issues specific to Japan. The meeting will bring together experts and members of academia, regulatory and drug development organisations for 2 days of intensive discussion, debates and updates.Dr Taubel's extensive experience in investigating ethnic differences and bridging ECG studies exploring physiological and drug induced effects makes him a world leading expert in the evaluation of effects of ethnicity on the ECG. His recent work includes studies in both Caucasian and Japanese participants using techniques such as an euglycaemic insulin clamp investigating the effects of food on the QT interval in a proper ICH E14 setting. He will present some of his latest data.Click here to view the full programWe invite you to be a part of this hugely informative event on current issues facing the industry and network with like-minded scientific professionals. A Business Development representative from Richmond Pharmacology will also be standing by for the duration of the workshop to discuss your prospective TQT study requirements and how we can benefit towards its total success.To arrange a face to face meeting or request a copy of our latest TQT publication,contact a member of our BD Team today.

Latest news

Recruiting breastfeeding mothers into clinical trials through transparent and sensitive conversations

April 30, 2024
Richmond Pharmacology's study on merotocin showed low transfer to breast milk, overcoming recruitment challenges through proximity to a maternity ward.
Read more

Announcement of Jorg Becoming President Elect

April 22, 2024
Richmond Pharmacology announces CEO Dr. Jorg Taubel's appointment as President Elect of Germany's AGAH, where he will enhance early-phase clinical research over a six-year term.
Read more

Events

AHA Hypertension Scientific Sessions 2024

5 - 8 September 2024
Dr. Jörg Taubel, CEO of Richmond Pharmacology, will be attending the Hypertension 2024 Scientific Sessions
View event